Principal Scientist, Cancer Pharmacology, Translational Research

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified checked Jun 7, 2026

Salary

$190K-$238K From the posting source checked Jun 20, 2026

401(k) match

Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$55,390 U.S. median for this role

Projected growth (BLS Employment Projections)

-0.1% - Decline

286% above the BLS role benchmark for teaching and education aggregate.

Posted salary is far from this role benchmark; treat it as low confidence.

Matched to SOC 25-2021 - Teaching and Education aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function

Teaching Education From the posting source checked Jun 20, 2026

Seniority

Principal From the posting source checked Jun 20, 2026

Schedule

Shift type

Not verified

Weekend work

Not verified

Company

Company stage

Late-stage From the posting source checked Jun 20, 2026

Equity

Offered Verified - SEC 10-K source checked Jun 20, 2026

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Principal Scientist, Cancer Pharmacology, Translational Research Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As a Principal Scientist in the Cancer Pharmacology team within the Translational Research group, in the Biomedical Discovery Research Department, you will: - Provide scientific and strategic leadership for RAS(ON) inhibitor programs by translating mechanistic insights in RAS biology into impactful pharmacology strategies and translational study plans. - Lead, mentor, and develop a high-performing group of in vivo scientists, fostering scientific excellence, innovation, and cross-functional collaboration. - Drive the design, execution, and interpretation of in vivo efficacy and PK/PD studies conducted internally and through external partners to advance oncology discovery and development programs. - Partner closely with the cross-functional quantitative modeling group to provide biological insight, translational context, and critical evaluation supporting PK/PD modeling efforts. - Influence portfolio progression through generation of high-impact data packages and contributions to regulatory submissions. - Serve as the in vivo pharmacology expert on cross-functional project

Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.